MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT.

Slides:



Advertisements
Similar presentations
R&D Financing by the Bill & Melinda Gates Foundation
Advertisements

FamiliesUSA The Neglected Tropical Diseases
WHO Expert Working Group on R&D and Financing January 2009 G-FINDER: Global Funding of Innovation for Neglected Diseases.
© IFPMA 2009 IFPMA to WHO EWG 12 Jan 09 1 Alicia D. Greenidge, Director General, IFPMA WHO Expert Working Group, Geneva, 12 Jan 2009 IFPMA Presentation.
Neglected Tropical Diseases and Malaria: The need for mapping.
What to include? Should EDCTP-2 be expanded to other fields? Marja Esveld, 29 September 2010.
Trends in TB R&D investment: Where is funding most needed? Lindsey Wu Policy Analyst Policy Cures
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
10 FACTS ON NEGLECTED TROPICAL DISEASES Fact 1 More than 1 billion people are affected by one or more neglected tropical diseases (NTDs). They are named.
Neglected Diseases: Student-driven efforts to address the innovation gap UAEM International Conference October 9, 2010.
Parasitic diseases: current and future challenges Data Source: Moran M, Guzman J, Abela Oversteegen L, Liyanage R, Omune B, Wu L, Chapman N, Gouglas D.
Don’t Neglect the NTDs! Rick Speare Emeritus Professor James Cook University, Townsville, Australia & Director, Tropical Health Solutions 31 October 2013.
Towards an ontology of vector- borne diseases: MalIDO, the first step.
Professor Alan Fenwick OBE SCI Imperial College London Schistosomiasis and STH control and elimination ICOSA (LF, Oncho and trachoma)
Achieving a ‘Grand Convergence’ in Global Health Chair: Richard Feachem, University of California, San Francisco Presenter: Dean Jamison, University of.
Global Health, NTDs and STHs Lunch and Learn September 19, 2012 Theresa W. Gyorkos Professor, McGill University
Source: National Health Profile-2008 (Provisional), CBHI Chikungunya Fever in India 2008 N.
Dengue Cases in India-2010 N Source: National Health Profile-2010 (Provisional), CBHI.
Source: National Health Profile-2007,CBHI AIDS Cases in India December-2007 N.
This wormy world: consequences, co-infections and the challenge of field-based study designs Professor Celia Holland Department of Zoology School of Natural.
Designing Strategies for Neglected Disease Research Lecture 1A Amy Kapczynski UC Berkeley Law From MSF Campaign for Access to Essential Medicines, AccessNews.
CENTER FOR BIOLOGICAL SEQUENCE ANALYSIS Technical University of Denmark - DTU Department of systems biology Biopeople Tutorial 2011 Immunological Bioinformatics.
Designing Strategies for Neglected Disease Research: What Innovations Do We Need? Julia Walsh MD MSc UCB School of Public Health
V S Mazumdar Professor and Head Department of Preventive and Social Medicine Medical College Baroda.
LESSON 13.2: PARASITIC INFECTIONS Module 13: Global Health Obj. 13.2: Identify the types and characteristics of common parasitic infections.
NTDs and eye health: lessons learnt and opportunities for collaboration Adrian D Hopkins Director: Mectizan Donation Program Task Force for Global Health.
Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases.
1 WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines.
Global Health Program Guiding Principles April 2002.
Universities Allied for Essential Medicine Central Michigan University Chapter Increasing Global Access to Medicine through Information Transfer and the.
T reatment A ction G roup Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis.
1 |1 | Key problems Neglected Tropical Diseases Hidden and silent : Key problems Complacency, lack of information and commitment Complacency, lack of information.
Innovation and Access: Intersection of Public Health and Intellectual Property EMP - Technical Briefing Seminar 30 October, 2012 WHO HQ, Geneva Zafar Mirza.
Neglected Tropical Diseases: Control & Research
WaterAid’s Presentation to the DPG - Health in Tanzania Namwaka Omari Ferdinandes Axweso Ibrahim Kabole, MD May At USAID-DSM.
The significance of Medical Parasitology. Prevalent infections worldwide Significant morbidity & mortality Significant impact on economic & social development.
CABI product training Global Health Tom Corser. Global Health Agenda ● CABI publishing and product overview ● Live product demo of CAB Direct including.
Alternative R&D Strategies for Drugs for Neglected Diseases: The Case & Possible Alternatives TACD IPR Meeting Washington Nov 1, 2002.
1 Thailand’s perspective on new incentive systems for R&D of medicines Sripen Tantivess International Health Policy Program Ministry of Public Health,
The Schistosomiasis Control Initiative Summary for 2012/13 and strategic direction for 2014/20 Professor Alan Fenwick OBE
Did you know... One in every six people on this globe suffers from a disease of poverty? One in every six people on this globe suffers from a disease.
RICHA PANDEY. Trademark – Brand Names (Crocin) Design – Shape/packaging Copyright – labels (look & feel) Patents.
Sustainability: The R&D Pipeline for Neglected Disease Vaccines Elizabeth L. Ponder, PhD May 4, 2011 Global Vaccines 202X: Access, Equity, Ethics 2-4 May.
UCL Workshop Dr Mary Moran Policy Cures December 2014.
Global Forum for Health Research Mumbai, September 12 to Rob Ridley Director, TDR Sustaining Priority Research for Neglected Tropical Diseases.
The Thaw （解冻）  1. Epidemic Status  2. Influence of Global Warming  3. Our Work.
Institute for Immunology and Informatics (iCubed) D. Spero icubed overview 2011 URI Biotechnology Program in Providence The College of the Environment.
TDR Target Diseases: Malaria Schistosomiasis African Sleeping Sickness Chagas Disease Lymphatic filariasis Onchocerciasis Leishmaniasis Leprosy Tuberculosis.
Population Age Structure BritainTanzania age.
The significance of Medical Parasitology
MALARIA IN KENYA JEREMY arvid ODERA CHEK. KENYA DEMOGRAPHIC AND SOCIO-ECONOMIC INFORMATION Population a : 32,020,244 (2002) Age structure a : ● 0-14.
Source:  First discovered in 1976 in Northern Zaire and Southern Sudan  Subsequent outbreaks - Cote d’Ivoire, Gabon and Uganda.
1 Economics of the Pharmaceutical Industry Prof. Brook K. Baker Northeastern University School of Law Health GAP (Global Access Project) UKZN – IP and.
Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.
Why WASH-NTDs Matter WASHplus Project April 2016.
USAID Neglected Tropical Diseases Program. 2 WHO 17 Neglected Tropical Diseases (NTDs) by Strategic Interventions London Declaration 10 NTDs USAID 5 NTDs.
#innovate4health July 20,
FAST TRACKING THE DESIGN AND DEVELOPMENT FOR VACCINES FOR “NEGLECTED DISEASES” DR GAURAV GUPTA , Head Viral and genetic engineered vaccines, Vaccine technology.
World Health Organization
World Health Organization
State of the TB Alliance
National School of Tropical Medicine An Assault on the Diseases of
APPMG December 17, 2008 Presented by Dr. John P. Rumunu (MPH, MB.BS)
Where we could be by 2015 and how to get there
Accessing Medicines in Africa Prospects and challenges
Neglected Tropical Diseases Hidden and silent : Key problems
Francophone Network for the elimination Neglected Tropical Diseases
ASPECTS OF COMPLICATIONS ARISING FROM NEGELCTED TROPICAL CO-INFECTIONS AND THEIR SOCIAL AND ECONOMIC IMPLICATIONS IN SUB SAHARAN AFRICA L.S. Luboobi, J.Y.T.
Neglected Tropical Diseases Hidden and silent : Key problems
Immunity to Infections – SPI XL –
Presentation transcript:

MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT

Policy Cures Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the developing world

Annual survey of global investment into R&D of new neglected disease products Neutral, comparable, comprehensive analysis Commissioned by the Bill & Melinda Gates Foundation 31 neglected diseases 134 product areas All R&D stages G-FINDER

$84.9m higher in 2011 than in 2007 Malaria – overall funding

Malaria – by product area Vaccines, diagnostics and vector control R&D ↑ Drug R&D → Basic research ↑

Who funds malaria R&D? Gates Foundation 26.3% US NIH 20.7% Industry (aggregate) 18.7% 66%

NTDs 50% 65% Buruli ulcer Dengue Kinetoplastids (Chagas, HAT, leishmaniasis) Helminths (lymphatic filariasis, STHs, cysticercosis, onchocerciasis, schistosomiasis) Leprosy Trachoma HIV/AIDS Malaria TB Diarrhoeal diseases Bacterial pneumonia & meningitis Salmonella infections Rheumatic fever Guinea worm disease Echinococcosis Foodborne trematode infections Rabies Yaws WHO classificationG-FINDER

NTDs – dengue, kinetoplastids and helminths

NTDs – leprosy, Buruli ulcer and trachoma $7.4m$5.8m $9.6m

Download the full report at

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.